Bionest

Look Beyond the US and Europe for Rare Disease Launches

Rest-of-world markets offer good opportunities for rare disease companies to expand their sales potential beyond what U.S. & E.U. markets offer, and the requirements for market entry should be considered at a high level early on.

Bionest

Coronavirus Impacts on Industry: Part 1

As the COVID-19 pandemic rages on, the effects of the virus are being felt not only by the global populace, but by the various sectors of the health care industry and those that support them.

Bionest

New Treatment Options for Hemoglobin-Based Blood Disorders

    Sickle cell disease is a group of inherited disorders that affects hemoglobin, the oxygen-carrying protein in red blood cells (RBCs), and causes these cells to distort in shape at low oxygen levels. This condition affects 1 in 500 Americans of African descent and 1 in 1,000-1,400 of Hispanic descent, as well as millions...

Bionest

The SMA Market: Assessing the Unknowns

Challenges and opportunities in the field of spinal muscular atrophy, including how new disease-modifying therapies are likely to change SMA’s course over time.